Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
37.628,48 -831,60 (-2,16%) EUR/USD
1,0725 +0,0024 (+0,23%) Bitcoin EUR
60.004,96 -2.120,68 (-3,41%) CMC Crypto 200
1.390,59 +8,01 (+0,58%)
Pfizer Inc. (0Q1N.IL)
| Chiusura precedente | 26,40 |
| Aperto | 26,29 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 26,28 - 26,29 |
| Intervallo di 52 settimane | 25,24 - 41,20 |
| Volume | |
| Media Volume | 402.796 |
| Capitalizzazione | 158,185B |
| Beta (5 anni mensile) | 0,57 |
| Rapporto PE (ttm) | 6,94 |
| EPS (ttm) | 3,76 |
| Prossima data utili | 01 mag 2024 |
| Rendimento e dividendo (futuro) | 1,64 (5,31%) |
| Data ex dividendo | 08 nov 2023 |
| Stima target 1A | N/D |
GlobeNewswireArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g
- GlobeNewswire
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP)NEW HAVEN, Conn. and NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.K. Innovative Licensing and Access Pathway Steering Group, which consists of The All Wales Therapeutics and Toxicology Centre (AWTTC), The Medicines and Healthcare products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence (NICE),
GlobeNewswireCarrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Collaboration expands Carrick’s clinical-stage Oncology programDUBLIN, Ireland and BOSTON, July 06, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical trial collaboration and supply agreement with Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE). This agreement covers the execution of a Phase 1b/2 clinical trial to evaluate the novel combination of Carrick’s sa
